Macular Degeneration Treatment in BC: Injections, Costs and Access

Last Updated: June 2026

Macular degeneration affects thousands of British Columbians each year, making it one of the leading causes of vision loss in adults over 50. Understanding your treatment options, associated costs, and how to navigate the BC healthcare system can help you access timely care and preserve your vision. This guide provides comprehensive information about macular degeneration treatment in BC, including what to expect from anti-VEGF injections, laser therapy, and the coverage available through MSP.

Understanding Macular Degeneration

Age-related macular degeneration (AMD) damages the macula, the central portion of the retina responsible for sharp, detailed vision. There are two primary forms of this condition:

Dry AMD accounts for approximately 80% to 90% of cases. This form progresses slowly as the macula thins over time. While there is currently no cure for dry AMD, nutritional supplements and lifestyle modifications may help slow progression in certain patients.

Wet AMD is less common but more aggressive. Abnormal blood vessels grow beneath the retina and leak fluid or blood, causing rapid vision loss if left untreated. Wet AMD requires prompt treatment, typically with anti-VEGF injections.

Early detection through regular eye examinations is critical for both forms. Many British Columbians experience vision changes without realizing the underlying cause, making routine screening essential for adults over 50.

Treatment Options Available in BC

Anti-VEGF Injection Therapy

Anti-VEGF (vascular endothelial growth factor) injections are the primary treatment for wet macular degeneration in BC. These medications block the growth of abnormal blood vessels and reduce fluid leakage in the retina. Common anti-VEGF medications used in BC include:

• Ranibizumab (Lucentis)
• Aflibercept (Eylea)
• Bevacizumab (Avastin), used off-label
• Faricimab (Vabysmo), a newer dual-action option

Treatment typically begins with a loading phase of monthly injections for the first three months, followed by ongoing maintenance injections every 4 to 12 weeks depending on your response. Most patients require treatment for several years, and some require indefinite treatment to maintain vision stability.

Laser Therapy

Photodynamic therapy (PDT) and thermal laser treatment are used less frequently than anti-VEGF injections but remain options for specific cases. PDT involves injecting a light-sensitive drug and activating it with a laser to seal leaking blood vessels. These treatments are typically reserved for patients who do not respond adequately to injection therapy or have specific lesion types.

Nutritional Supplements for Dry AMD

The AREDS2 formulation, a specific combination of vitamins and minerals, may slow progression in patients with intermediate dry AMD. This supplement combination includes vitamin C, vitamin E, zinc, copper, lutein, and zeaxanthin. Patients should discuss supplementation with their ophthalmologist before starting any regimen.

Macular Degeneration Treatment Costs in BC

Understanding the financial aspects of macular degeneration treatment helps British Columbians plan for care and explore all coverage options.

Anti-VEGF Injection Costs

The cost per anti-VEGF injection in BC ranges significantly depending on the medication:

• Bevacizumab (Avastin): $50 to $100 per injection (off-label, lowest cost)
• Ranibizumab (Lucentis): $1,400 to $1,800 per injection
• Aflibercept (Eylea): $1,200 to $1,600 per injection
• Faricimab (Vabysmo): $1,500 to $2,000 per injection

Given that patients may require 8 to 12 injections annually, total yearly treatment costs can range from $800 with Avastin to over $20,000 with newer medications.

MSP Coverage for Macular Degeneration Treatment

The BC Medical Services Plan covers ophthalmologist consultations and the injection procedure itself. However, coverage for the anti-VEGF medication varies:

BC PharmaCare Special Authority: PharmaCare provides coverage for certain anti-VEGF medications through the Special Authority program. Your ophthalmologist must submit an application demonstrating medical necessity. Once approved, PharmaCare covers most of the medication cost, with patients responsible for any applicable deductibles based on income.

Fair PharmaCare: British Columbians enrolled in Fair PharmaCare have medication costs covered once they reach their annual deductible. Deductibles are calculated based on household income, ranging from $0 for low-income families to approximately 3% of net income for higher earners.

Patients without PharmaCare coverage or those awaiting Special Authority approval may face significant out-of-pocket costs. Private insurance plans often provide additional coverage for prescription medications, reducing personal expenses.

Accessing Macular Degeneration Care in BC

The Referral Process

Accessing specialized macular degeneration treatment in BC typically follows this pathway:

1. Initial Detection: An optometrist or family physician identifies signs of macular degeneration during a routine examination or when investigating vision complaints.
2. Referral to Ophthalmology: Your primary care provider or optometrist submits a referral to a retinal specialist or general ophthalmologist. Our Specialist Access Guide provides detailed information about navigating this process.
3. Diagnostic Assessment: The ophthalmologist performs comprehensive testing, including optical coherence tomography (OCT) and fluorescein angiography, to confirm diagnosis and determine the appropriate treatment approach.
4. Treatment Initiation: For wet AMD, treatment typically begins within days to weeks of diagnosis due to the condition's progressive nature.

Wait Times Across BC

Wait times for ophthalmology services vary significantly across British Columbia. Current estimated wait times for initial ophthalmology consultations include:

• Vancouver: 6 to 12 weeks for routine referrals, expedited for urgent cases
• Surrey and Burnaby: 8 to 14 weeks for non-urgent referrals
• Richmond: 6 to 10 weeks
• Victoria: 8 to 12 weeks
• Kelowna: 10 to 16 weeks
• Abbotsford: 10 to 14 weeks

Urgent referrals for suspected wet AMD are typically prioritized, with many retinal specialists seeing patients within 1 to 2 weeks when rapid vision changes are documented. For comprehensive information about healthcare wait times across the province, visit our BC Healthcare Wait Times resource.

Major Treatment Centres

Specialized retinal care is available at several facilities across BC:

Vancouver Coastal Health Region: Vancouver General Hospital Eye Care Centre, multiple private ophthalmology clinics in Vancouver, Burnaby, and Richmond

Fraser Health Region: Surrey Memorial Hospital, Royal Columbian Hospital in New Westminster, and private clinics throughout Surrey, Burnaby, and Abbotsford

Interior Health: Kelowna General Hospital and associated ophthalmology practices

Island Health: Royal Jubilee Hospital in Victoria, Nanaimo Regional General Hospital

Private Options and Faster Access

Some British Columbians choose private diagnostic services to expedite their care pathway. Private clinics in Vancouver, Victoria, and Kelowna offer retinal imaging and OCT scans with shorter wait times, often within days rather than weeks. These results can then be shared with your treating ophthalmologist to facilitate faster treatment decisions. Learn more about these options in our Private Diagnostics in BC guide.

Private ophthalmology clinics also provide anti-VEGF injection services, sometimes with greater scheduling flexibility than hospital-based programs. However, medication costs remain similar regardless of where treatment is administered.

Living with Macular Degeneration in BC

Vision Rehabilitation Services

BC offers vision rehabilitation services for individuals experiencing significant vision loss from macular degeneration. The CNIB Foundation provides programs throughout the province, including low vision assessments, adaptive technology training, and independent living skills support.

Driving Considerations

Macular degeneration can affect driving eligibility. ICBC requires minimum visual acuity standards for driver licensing. Patients with significant vision loss should discuss driving safety with their ophthalmologist and may require formal visual field testing for licensing purposes.

Ongoing Monitoring

Regular monitoring is essential for all macular degeneration patients. Those with dry AMD typically require examinations every 6 to 12 months to detect any progression to the wet form. Patients receiving anti-VEGF treatment are monitored at each injection visit, with imaging performed regularly to assess treatment response.

Questions to Ask Your Eye Care Provider

When consulting with your ophthalmologist about macular degeneration, consider asking:

• What type and stage of macular degeneration do I have?
• Which anti-VEGF medication do you recommend and why?
• How frequently will I need injections?
• What are the risks and potential side effects of treatment?
• Will PharmaCare cover my medication costs?
• What symptoms should prompt me to seek immediate care?
• Are there clinical trials available in BC for new treatments?

Additional Resources

For more information about macular degeneration and vision health, British Columbians can access these resources:

• HealthLinkBC (8-1-1) for 24/7 health information and advice
• CNIB Foundation BC for vision loss support services
• Macular Degeneration Canada for patient education and support groups
• BC PharmaCare for medication coverage information

Early detection and consistent treatment offer the best outcomes for preserving vision in macular degeneration patients. By understanding your options and navigating the BC healthcare system effectively, you can access the care you need to protect your sight.

A Boost Commerce Group Property | boostcommercegroup.ca